Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done
The growing evidence that tumors can evade the immune system through a variety of mechanisms makes understanding these processes critical to implementing new and more effective forms of immunotherapy. In Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done, leading...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Totowa, NJ
Humana Press
2004
|
| Schriftenreihe: | Current Clinical Oncology
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | The growing evidence that tumors can evade the immune system through a variety of mechanisms makes understanding these processes critical to implementing new and more effective forms of immunotherapy. In Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done, leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors) that may serve as biomarkers for patient prognosis. They discuss the means by which immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells are also outlined. State-of-the-art and insightful, Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done illuminates the possibilities for developing effective immunotherapies that can block the mechanisms by which tumors evade the immune system in different histologic types of tumors |
| Beschreibung: | 1 Online-Ressource (XVII, 386 p) |
| ISBN: | 9781592597437 |
| DOI: | 10.1007/978-1-59259-743-7 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046146623 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s2004 |||| o||u| ||||||eng d | ||
| 020 | |a 9781592597437 |9 978-1-59259-743-7 | ||
| 024 | 7 | |a 10.1007/978-1-59259-743-7 |2 doi | |
| 035 | |a (ZDB-2-SME)978-1-59259-743-7 | ||
| 035 | |a (OCoLC)1119002667 | ||
| 035 | |a (DE-599)BVBBV046146623 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.994 |2 23 | |
| 245 | 1 | 0 | |a Cancer Immunotherapy at the Crossroads |b How Tumors Evade Immunity and What Can Be Done |c edited by James H. Finke, Ronald M. Bukowski |
| 264 | 1 | |a Totowa, NJ |b Humana Press |c 2004 | |
| 300 | |a 1 Online-Ressource (XVII, 386 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Current Clinical Oncology | |
| 520 | |a The growing evidence that tumors can evade the immune system through a variety of mechanisms makes understanding these processes critical to implementing new and more effective forms of immunotherapy. In Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done, leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors) that may serve as biomarkers for patient prognosis. They discuss the means by which immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells are also outlined. State-of-the-art and insightful, Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done illuminates the possibilities for developing effective immunotherapies that can block the mechanisms by which tumors evade the immune system in different histologic types of tumors | ||
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Oncology | |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Immuntherapie |0 (DE-588)4026640-0 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Immuntherapie |0 (DE-588)4026640-0 |D s |
| 689 | 0 | |8 1\p |5 DE-604 | |
| 700 | 1 | |a Finke, James H. |4 edt | |
| 700 | 1 | |a Bukowski, Ronald M. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781468498448 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781588291837 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781468498431 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-59259-743-7 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031526808 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u https://doi.org/10.1007/978-1-59259-743-7 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180484838653952 |
|---|---|
| any_adam_object | |
| author2 | Finke, James H. Bukowski, Ronald M. |
| author2_role | edt edt |
| author2_variant | j h f jh jhf r m b rm rmb |
| author_facet | Finke, James H. Bukowski, Ronald M. |
| building | Verbundindex |
| bvnumber | BV046146623 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-1-59259-743-7 (OCoLC)1119002667 (DE-599)BVBBV046146623 |
| dewey-full | 616.994 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994 |
| dewey-search | 616.994 |
| dewey-sort | 3616.994 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-1-59259-743-7 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03438nmm a2200505zc 4500</leader><controlfield tag="001">BV046146623</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s2004 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781592597437</subfield><subfield code="9">978-1-59259-743-7</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-59259-743-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-1-59259-743-7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119002667</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046146623</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cancer Immunotherapy at the Crossroads</subfield><subfield code="b">How Tumors Evade Immunity and What Can Be Done</subfield><subfield code="c">edited by James H. Finke, Ronald M. Bukowski</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Totowa, NJ</subfield><subfield code="b">Humana Press</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XVII, 386 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Current Clinical Oncology</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The growing evidence that tumors can evade the immune system through a variety of mechanisms makes understanding these processes critical to implementing new and more effective forms of immunotherapy. In Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done, leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors) that may serve as biomarkers for patient prognosis. They discuss the means by which immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells are also outlined. State-of-the-art and insightful, Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done illuminates the possibilities for developing effective immunotherapies that can block the mechanisms by which tumors evade the immune system in different histologic types of tumors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Finke, James H.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bukowski, Ronald M.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781468498448</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781588291837</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781468498431</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-59259-743-7</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031526808</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-59259-743-7</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV046146623 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:30Z |
| institution | BVB |
| isbn | 9781592597437 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031526808 |
| oclc_num | 1119002667 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XVII, 386 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 2004 |
| publishDateSearch | 2004 |
| publishDateSort | 2004 |
| publisher | Humana Press |
| record_format | marc |
| series2 | Current Clinical Oncology |
| spelling | Cancer Immunotherapy at the Crossroads How Tumors Evade Immunity and What Can Be Done edited by James H. Finke, Ronald M. Bukowski Totowa, NJ Humana Press 2004 1 Online-Ressource (XVII, 386 p) txt rdacontent c rdamedia cr rdacarrier Current Clinical Oncology The growing evidence that tumors can evade the immune system through a variety of mechanisms makes understanding these processes critical to implementing new and more effective forms of immunotherapy. In Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done, leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors) that may serve as biomarkers for patient prognosis. They discuss the means by which immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells are also outlined. State-of-the-art and insightful, Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done illuminates the possibilities for developing effective immunotherapies that can block the mechanisms by which tumors evade the immune system in different histologic types of tumors Oncology Oncology Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Immuntherapie (DE-588)4026640-0 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 s Immuntherapie (DE-588)4026640-0 s 1\p DE-604 Finke, James H. edt Bukowski, Ronald M. edt Erscheint auch als Druck-Ausgabe 9781468498448 Erscheint auch als Druck-Ausgabe 9781588291837 Erscheint auch als Druck-Ausgabe 9781468498431 https://doi.org/10.1007/978-1-59259-743-7 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Cancer Immunotherapy at the Crossroads How Tumors Evade Immunity and What Can Be Done Oncology Oncology Krebs Medizin (DE-588)4073781-0 gnd Immuntherapie (DE-588)4026640-0 gnd |
| subject_GND | (DE-588)4073781-0 (DE-588)4026640-0 |
| title | Cancer Immunotherapy at the Crossroads How Tumors Evade Immunity and What Can Be Done |
| title_auth | Cancer Immunotherapy at the Crossroads How Tumors Evade Immunity and What Can Be Done |
| title_exact_search | Cancer Immunotherapy at the Crossroads How Tumors Evade Immunity and What Can Be Done |
| title_full | Cancer Immunotherapy at the Crossroads How Tumors Evade Immunity and What Can Be Done edited by James H. Finke, Ronald M. Bukowski |
| title_fullStr | Cancer Immunotherapy at the Crossroads How Tumors Evade Immunity and What Can Be Done edited by James H. Finke, Ronald M. Bukowski |
| title_full_unstemmed | Cancer Immunotherapy at the Crossroads How Tumors Evade Immunity and What Can Be Done edited by James H. Finke, Ronald M. Bukowski |
| title_short | Cancer Immunotherapy at the Crossroads |
| title_sort | cancer immunotherapy at the crossroads how tumors evade immunity and what can be done |
| title_sub | How Tumors Evade Immunity and What Can Be Done |
| topic | Oncology Oncology Krebs Medizin (DE-588)4073781-0 gnd Immuntherapie (DE-588)4026640-0 gnd |
| topic_facet | Oncology Oncology Krebs Medizin Immuntherapie |
| url | https://doi.org/10.1007/978-1-59259-743-7 |
| work_keys_str_mv | AT finkejamesh cancerimmunotherapyatthecrossroadshowtumorsevadeimmunityandwhatcanbedone AT bukowskironaldm cancerimmunotherapyatthecrossroadshowtumorsevadeimmunityandwhatcanbedone |